<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>希望的使者：两种mRNA Covid-19疫苗预示着疫苗学的新时代 Messengers of hope: two mRNA Covid-19 vaccines herald a new era for vaccinology</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">Messengers of hope: two mRNA Covid-19 vaccines herald a new era for vaccinology<br/>希望的使者：两种mRNA Covid-19疫苗预示着疫苗学的新时代 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2020-12-30 19:46:23</div><div class="page_narrow text-break page_content"><p>Emergency Use Authorizations for two mRNA COVID-19 vaccines represent a turning point in the pandemic. They also herald a new era for vaccinology.</p><p>两种mRNA COVID-19疫苗的紧急使用授权代表了大流行的转折点。他们也预示着疫苗学的新时代。</p><p>     One year ago, few would have tipped mRNA vaccines as the world’s best hope. They had been tested in a handful of human trials. They had been injected into fewer than 1,800 people. And efficacy data in humans were both sparse and  underwhelming. Twelve months on, ~34,000 people have received mRNA immunizations in human trials of two mRNA products targeting SARS-CoV-2 spike (S) protein. Both products provide impressive efficacy, notably in individuals 65 or older. Emergency Use Authorizations of BioNTech/Pfizer’s  BNT162b2 and Moderna’s  mRNA-1273 vaccines raise hopes that the pandemic could finally turn a corner. They may even presage an era where vaccines are designed in computers, iteratively optimized in discovery and manufactured on demand — all without expensive and finicky cell culture.</p><p>     一年前，很少有人会把mRNA疫苗作为世界上最大的希望。他们已经在少数人体试验中进行了测试。他们被注射到不到1800人中。而且对人体的疗效数据既稀疏又不充分。十二个月以来，约有34,000人在人体试验中针对两种针对SARS-CoV-2峰值（S）蛋白的mRNA产品进行了免疫接种。两种产品均具有令人印象深刻的功效，特别是对于65岁或65岁以上的人群。 BioNTech / Pfizer的BNT162b2和Moderna的mRNA-1273疫苗的紧急使用授权引起了人们对该疾病最终可能转危的希望。他们甚至预示着一个时代，在这个时代里，可以在计算机上设计疫苗，在发现过程中反复优化并按需生产—所有这些过程都不需要昂贵且费力的细胞培养。</p><p> The new nucleoside-modified mRNA vaccines are chemicals that have been almost fully disclosed. They incorporate a trinucleotide cap 1 analog ((m 2 7,3′- O)Gppp(m 2′- O)ApG), contain  N 1-methylpseudouridine instead of uridine, and encode an optimized ( P2-mutated) full-length S glycoprotein encapsulated in lipid nanoparticles (LNPs) containing polyethylene glycol and cholesterol. The  BNT162b2 LNP  also contains (4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) and 1,2-distearoyl- sn-glycero-3-phosphocholine, whereas  Moderna’s LNP contains SM-102 (most likely  heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate) and  1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG). The BioNTech vaccine is administered intramuscularly (IM) as two 30-μg doses 21 days apart, the Moderna product as two 100-μg IM doses 28 days apart.</p><p> 新的核苷修饰的mRNA疫苗是几乎已完全公开的化学药品。它们掺入了三核苷酸帽1类似物（（m 2 7,3'-O）Gppp（m 2'-O）ApG），包含N 1-甲基伪杜鹃碱而不是尿苷，并编码了优化的（P2突变）全长S糖蛋白封装在包含聚乙二醇和胆固醇的脂质纳米颗粒（LNP）中。 BNT162b2 LNP还包含（4-羟丁基）氮杂二基）双（己烷-6,1-二基）双（2-己基癸酸）和1,2-二硬脂酰基-sn-甘油-3-磷酸胆碱，而Moderna的LNP包含SM-102 （最有可能是庚烷9-基8-（（2-羟乙基）（6-氧代-6-（十一烷基氧基）己基）氨基）辛酸酯）和1,2-二肉豆蔻酰基-rac-甘油-3-甲氧基聚乙二醇-2000（ PEG）。 BioNTech疫苗以21天间隔两次30μg的剂量肌内注射（IM），Moderna产品以28天间隔两次两次的100μgIM剂量进行肌内注射。</p><p> Two other types of synthetic mRNA LNP COVID-19 vaccines have also entered testing: CureVac just initiated a  phase 2/3 trial for its  unmodified uridine-deficient mRNA product ( CVnCoV), and during the summer  Arcturus Therapeutics and  Imperial College London commenced phase 1 testing of  self-amplifying RNA vaccines based on an alphavirus that encode non-structural proteins to replicate the S-protein immunogen.</p><p> 另外两种其他类型的合成mRNA LNP COVID-19疫苗也已进入测试：CureVac刚刚对其未修饰的尿苷缺陷型mRNA产品（CVnCoV）进行了2/3期试验，并且在夏季Arcturus Therapeutics和伦敦帝国大学开始了第一阶段基于α病毒的自我扩增RNA疫苗的测试，该疫苗编码非结构蛋白以复制S蛋白免疫原。</p><p> The BioNTech and Moderna vaccines work spectacularly. Of the 20,033 people who received  BNT162b2, efficacy outcomes one week after the second dose were 95%, a level consistent (≥93%) across all demographic subgroups. In the 13,218 participants receiving two doses of  Moderna’s vaccine, efficacy was 93.4% for people 18 to 64 years old and 86.4% for those ages 65 and up. For both products, adverse events elevated in the vaccine arm of the trial included fatigue, fever, headache, myalgia, arthralgia, pain/swelling at the injection site, lymphadenopathy, nausea, erythema, Bell’s palsy and appendicitis.</p><p> BioNTech和Moderna疫苗的效果惊人。在接受BNT162b2治疗的20,033名患者中，第二剂一星期后的疗效结果为95％，在所有人口统计学亚组中的水平一致（≥93％）。在接受了两剂Moderna疫苗接种的13,218名参与者中，18至64岁人群的有效率为93.4％，65岁及以上人群的有效率为86.4％。对于这两种产品，试验疫苗组中升高的不良反应包括疲劳，发烧，头痛，肌痛，关节痛，注射部位疼痛/肿胀，淋巴结肿大，恶心，红斑，贝尔氏麻痹和阑尾炎。</p><p> This triumph for RNA vaccine development has been three decades in the making. The first reports that foreign mRNA could  express protein and  induce cellular immunity when injected into mouse muscle came in the 1990s. Until the early noughts, however, progress was dogged by inflammatory reactions mediated by innate immune sensors for double-stranded (ds)RNA (for example, cytoplasmic protein kinase R (PKR) and 2′-5′-oligoadenylate synthetase, IFIT1, MDA5 and RIG-I) and for single-stranded RNA (for example, endosomal Toll-like receptor 3 (TLR3), TLR7 and TLR8). This reactogenicity, together with mRNA’s fragility (to RNases), large size (thousands of bases) and mediocre potency, led to widespread skepticism around the modality.</p><p> RNA疫苗开发的胜利已经进行了三十年。 1990年代首次报道外源mRNA可以在小鼠肌肉中表达蛋白质并诱导细胞免疫。然而，直到早期，通过先天免疫传感器介导的双链（ds）RNA（例如，胞质蛋白激酶R（PKR）和2'-5'-寡腺苷酸合成酶IFIT1，MDA5）介导的炎症反应仍在努力和RIG-1）和单链RNA（例如，内体Toll样受体3（TLR3），TLR7和TLR8）。这种反应原性，再加上mRNA的易碎性（对RNases的脆弱性），大尺寸（数千个碱基）和中等效力，导致人们对该模式普遍持怀疑态度。</p><p> A breakthrough came in  2005 when Katalin Karikó, Drew Weissman and their colleagues demonstrated that nucleoside modifications, such as pseudouridine and 5-methylcytidine, ablate TLR signaling (and  later when they showed similar dampening of PKR activation). That modified RNA actually produces more protein than unmodified mRNA was a big surprise. Reactogenicity was addressed via codon optimization and removal of dsRNA contaminant from the in vitro transcription reaction by various purification methods.</p><p> 2005年取得了突破，当时KatalinKarikó，Drew Weissman及其同事证明了核苷修饰（例如伪尿苷和5-甲基胞苷）消除了TLR信号传导（后来又显示出类似的PKR激活抑制作用）。修饰的RNA实际上比未修饰的mRNA产生更多的蛋白质，这是一个很大的惊喜。反应原性通过密码子优化和通过各种纯化方法从体外转录反应中去除dsRNA污染物来解决。 </p><p> Immune reactivity was not the only problem, however. As with other nucleic acid modalities, mRNAs are large molecules to get into cells — either via ex vivo delivery to cells (for example, as in dendritic cell cancer vaccines) or direct parenteral injection with or without a carrier. Many carriers were tried, including  protamine,  cationic liposomes,  cationic nanoemulsions,  dendrimers,  polymers and LNPs. In 2012, Tekmira Pharmaceuticals’ ionizable LNPs, which galvanized Alnylam’s siRNA programs, began testing for mRNA; the same year, Novartis vaccines (now part of GlaxoSmithKline)  showed that ionizable LNPs could potentiate a self-amplifying RNA vaccine. Today, ionizable LNPs are the carrier of choice.</p><p>免疫反应不是唯一的问题。与其他核酸形式一样，mRNA是进入细胞的大分子-通过离体递送至细胞（例如，在树突状细胞癌疫苗中）或直接胃肠外注射（含或不含载体）进入细胞。尝试了许多载体，包括鱼精蛋白，阳离子脂质体，阳离子纳米乳剂，树状聚合物，聚合物和LNP。在2012年，刺激了Alnylam的siRNA程序的Tekmira Pharmaceuticals的可电离LNP，开始测试mRNA；同年，诺华疫苗（现在是葛兰素史克公司的一部分）表明，可电离的LNP可以增强自扩增RNA疫苗。如今，可电离的LNP已成为选择的载体。</p><p> Over the years, mRNA stability and translation efficiency has also been tuned by optimizing regulatory elements in the  5′ and  3′ untranslated regions,  poly(A) tail length and  codon usage in the construct. Similarly, mRNA–LNP formulation is moving from macroscale mixing to more reproducible  microfluidic mixing devices.</p><p> 多年来，还通过优化5'和3'非翻译区的调控元件，poly（A）尾长和构建体密码子使用来调节mRNA的稳定性和翻译效率。同样，mRNA–LNP制剂正从大规模混合技术转向更具可再现性的微流体混合设备。</p><p> Unlike DNA vaccines, mRNA vaccines do not have to cross the nuclear envelope, they pose no risk of genomic integration, and they work in both dividing and non-dividing cells. Unlike protein and peptide vaccines, they are not restricted by major histocompatibility complex haplotype. That said, they have burdensome  cold-chain requirements and are currently the  most expensive COVID-19 vaccines.</p><p> 与DNA疫苗不同，mRNA疫苗不必越过核膜，它们不会造成基因组整合的风险，并且可以在分裂和非分裂细胞中发挥作用。与蛋白质和肽疫苗不同，它们不受主要组织相容性复合物单倍型的限制。也就是说，它们具有繁重的冷链需求，并且是目前最昂贵的COVID-19疫苗。</p><p> What is perhaps most exciting is the potential for mRNA as a rapid and generic platform for any desired immunogen(s). As upstream computational design and downstream processing and manufacture are standardized, custom work will mostly involve optimizing specific mRNA constructs to express efficiently in cells of interest. For SARS-CoV-2, Moderna was able to create mRNA-1273 in just six weeks after  disclosure of the draft viral genome — a record turnaround for a vaccine candidate. For future pandemics, vaccine templates could even be prepared in advance for more rapid deployment.</p><p> 也许最令人兴奋的是mRNA作为任何所需免疫原的快速通用平台的潜力。由于上游计算设计以及下游加工和制造已标准化，定制工作将主要涉及优化特定的mRNA构建以在目标细胞中有效表达。对于SARS-CoV-2，Moderna能够在披露病毒基因组草案后的短短六周内创造出mRNA-1273，这是候选疫苗的创纪录转机。对于未来的大流行，甚至可以提前准备疫苗模板以更快地部署。</p><p> By January 2022, we will know whether the promise is realized. By then, millions of people will have received these vaccines. Pooled data from  VAERS,  Sentinel and other  initiatives will provide a clearer picture of rare serious adverse events associated with immunization, such as severe allergic reactions to PEG. And burning issues beyond safety — whether these products can be used in pregnant women or children (given  multisystem inflammatory syndrome), whether they afford long-term protection and whether asymptomatic vaccinated individuals are capable of transmission — will be answered.</p><p> 到2022年1月，我们将知道诺言是否实现。届时，将有数百万人接种这些疫苗。来自VAERS，Sentinel和其他计划的汇总数据将提供与免疫相关的罕见严重不良事件（例如对PEG的严重过敏反应）的更清晰图片。将会解决超出安全性的紧迫问题-这些产品是否可用于孕妇或儿童（患有多系统炎症综合症），是否可以长期提供保护，以及无症状的疫苗接种者是否具有传播能力。</p><p> For now, though, these vaccines represent a new hope: the beginning of the end for this pandemic — and the advent of a new era in vaccinology.</p><p> 不过，目前来看，这些疫苗代表了新的希望：这种大流行病终结的开始-疫苗学新时代的到来。 </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://www.nature.com/articles/s41587-020-00807-1">https://www.nature.com/articles/s41587-020-00807-1</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/疫苗/">#疫苗</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/hope/">#hope</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>